Clinical Trials

Study Title:
Phase 3, Multicenter, Double Blind, Randomized, Placebo Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF 302)

For more information about the trial above please contact the study team:

Principal Investigator, Theodore Gourdin, at

Study Coordinator, Carly Fecio, at